Show simple item record

Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer

dc.contributor.authorKerbrat, P.en
dc.contributor.authorDieras, V.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorRavaud, A.en
dc.contributor.authorWanders, J.en
dc.contributor.authorFumoleau, P.en
dc.creatorKerbrat, P.en
dc.creatorDieras, V.en
dc.creatorPavlidis, Nicholasen
dc.creatorRavaud, A.en
dc.creatorWanders, J.en
dc.creatorFumoleau, P.en
dc.date.accessioned2018-06-22T09:53:46Z
dc.date.available2018-06-22T09:53:46Z
dc.date.issued2003
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42011
dc.description.abstractLU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had been previously treated with two lines of chemotherapy for advanced disease. Patients received LU 103793 at a dose of 2.5 mg/m2/day over 5 min for 5 consecutive days every 3 weeks. Thirty-four patients were enrolled and 23 patients were eligible for the evaluation of efficacy. Eleven patients experienced grade 4 neutropenia. Other related grade 3/4 adverse events included asthenia (three patients), stomatitis (1), myalgia (1) and increase of serum bilirubin (2). The main toxicity was hypertension occurring in seven out of 34 patients. There were no objective responses, 7 patients had stable disease. These results do not support the further evaluation of LU 103793 in metastatic breast cancer patients using this dose and schedule. © 2003 Elsevier Science Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceEuropean journal of canceren
dc.subjectArticleen
dc.subjectFemaleen
dc.subjectAntineoplastic agentsen
dc.subjectCancer chemotherapyen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectDrug responseen
dc.subjectPriority journalen
dc.subjectAlopeciaen
dc.subjectAnemiaen
dc.subjectAnorexiaen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectConstipationen
dc.subjectControlled clinical trialen
dc.subjectDiarrheaen
dc.subjectDrug efficacyen
dc.subjectInfectionen
dc.subjectLeukopeniaen
dc.subjectMyalgiaen
dc.subjectNeutropeniaen
dc.subjectPhase 2 clinical trialen
dc.subjectStomatitisen
dc.subjectThrombocytopeniaen
dc.subjectDrug tolerabilityen
dc.subjectFeveren
dc.subjectMetastasisen
dc.subjectNeoplasm metastasisen
dc.subjectMalaiseen
dc.subjectHypertensionen
dc.subjectVomitingen
dc.subjectBreast canceren
dc.subjectBreast carcinomaen
dc.subjectNauseaen
dc.subjectDose calculationen
dc.subjectBilirubin blood levelen
dc.subjectHyperbilirubinemiaen
dc.subjectBilirubinen
dc.subjectPhase iien
dc.subjectHeadacheen
dc.subjectAstheniaen
dc.subjectTimeen
dc.subjectCemadotinen
dc.subjectDolastatinen
dc.subjectHearten
dc.subjectLiveren
dc.subjectLu 103793en
dc.subjectOligopeptidesen
dc.titlePhase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast canceren
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/S0959-8049(02)00531-2
dc.description.volume39
dc.description.issue3
dc.description.startingpage317
dc.description.endingpage320
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record